The management of urothelial carcinoma (UC) has rapidly advanced in recent years with
new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However …

The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of
a subset of patients with urothelial carcinomas (UC). Growing evidence from preclinical …

Simple Summary Around 20% of advanced bladder cancer patients carry unfavorable
genetic alterations in the fibroblast growth factor receptor 3 (FGFR3) gene. This review …

Introduction: The recent approval of erdafitinib and the emergence of other potent and
selective fibroblast growth factor receptor (FGFR) inhibitors (FGFRi's) are shifting the …

Opinion statement As we come to better understand cancer genomics, we are increasingly
shifting towards precision medicine. FGFR has been elucidated as one of the oncogenic …

Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several
cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown …

The treatment of metastatic urothelial carcinoma has dramatically changed over the past
decade with the approval of several therapies from multiple drug classes including immune …

Molecular analysis has identified subsets of urothelial carcinoma (UC) expressing distinct
genetic signatures. Genomic alterations in the oncogenic fibroblast growth factor receptor 3 …

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment
approach for selected patients with urothelial cancer (UC). These agents are changing the …

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III
trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility …